UNSPSC 51334420: Cloxypendyl dihydrochloride

This classification denotes an antipsychotic agent with the molecular formula C20H25ClN4OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JL21P191Z6, chemically known as 1-piperazineethanol, 4-(3-(3-chloro-10h-pyrido(3,2-b)(1,4)benzothiazin-10-yl)propyl)-, dihydrochloride, but more generally known as cloxypendyl dihydrochloride, which bears US NIH Compound Identifier 209399.

European Medicines Agency schedules cloxypendyl dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06786MIG. Most nations, for tariff purposes, schedule cloxypendyl dihydrochloride under HS 29349990. SMILES: C1CCC2C(C1)N(C3C(CC(CN3)CL)S2)CCCN4CCN(CC4)CCO.CL.CL.

UNSPSC 51334420 Cloxypendyl dihydrochloride is a Commodity code under which state and local governments procure pharmaceutical and medical countermeasure products. The recent activity in this code shows procurement of naloxone and drug deactivation systems rather than cloxypendyl dihydrochloride specifically, suggesting the code is being applied to a broader category of opioid-response and harm-reduction pharmaceuticals and medical devices that state and local health and public safety agencies are acquiring to support community health and overdose-response initiatives. Issuing bodies under this code include county health departments and public health authorities sourcing these products for emergency response and community health programs.

Seminole County, Florida posted the most recent identified opportunity under this code: IFB60459723LAS, an invitation for bid for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The bid closed July 26, 2023, and required vendors to submit electronic bids through the county's e-Procurement Portal with all shipping and delivery costs included. The contract carried an initial two-year term with one-year renewal option, and vendors were required to maintain workers' compensation, commercial general liability, and professional liability insurance, comply with E-Verify, and submit drug-free workplace certifications. The procurement cited potential FEMA funding, introducing federal compliance requirements. Recent activity is sparse under this code; the single identified opportunity is from Florida and dates to mid-2023, suggesting limited current market activity or misalignment between the code classification and the actual pharmaceutical products being procured by state and local agencies.